Rendu-Osler disease: treatment with oestrogen/progestagen versus octreotide.

Détails

ID Serval
serval:BIB_0E8F4514F6CF
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Institution
Titre
Rendu-Osler disease: treatment with oestrogen/progestagen versus octreotide.
Périodique
BMJ Case Reports
Auteur⸱e⸱s
Jeanneret S., Regazzoni L., Favrat B.
ISSN
1757-790X (Electronic)
Statut éditorial
Publié
Date de publication
2011
Volume
2011
Numéro
23 February
Pages
bcr1120103534
Langue
anglais
Notes
Publication types: Case Reports ; Journal Article Publication Status: epublish
Résumé
In Rendu-Osler disease, haemorrhages due to gastrointestinal vascular malformations are common. Surgical and endoscopic treatments for haemorrhage due to gastrointestinal vascular malformations are compromised when lesions are diffuse, escape identification or are inaccessible to treatment. Hormonal treatment with oestrogen and progestagens is still controversial based on contradictory results from two randomised clinical trials. Although somatostatin and its long-acting analogue, octreotide, have been reported to be beneficial in preventing rebleeding, there is no consensus on this type of treatment. This case report shows how the combination of ethinyloestradiol and norethisterone markedly reduced the need for blood transfusions with few side effects in one patient; in comparison, octreotide seems less effective but this could be related to a worsening of the disease.
Mots-clé
Aged, Estrogens/therapeutic use, Humans, Male, Octreotide/therapeutic use, Progestins/therapeutic use, Telangiectasia, Hereditary Hemorrhagic/drug therapy
Pubmed
Création de la notice
25/02/2011 18:28
Dernière modification de la notice
20/08/2019 13:35
Données d'usage